199 related articles for article (PubMed ID: 22126283)
21. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
[TBL] [Abstract][Full Text] [Related]
22. The role of DOT1L in the maintenance of leukemia gene expression.
Wang X; Chen CW; Armstrong SA
Curr Opin Genet Dev; 2016 Feb; 36():68-72. PubMed ID: 27151433
[TBL] [Abstract][Full Text] [Related]
23. MLL translocations, histone modifications and leukaemia stem-cell development.
Krivtsov AV; Armstrong SA
Nat Rev Cancer; 2007 Nov; 7(11):823-33. PubMed ID: 17957188
[TBL] [Abstract][Full Text] [Related]
24. The emerging roles of DOT1L in leukemia and normal development.
McLean CM; Karemaker ID; van Leeuwen F
Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
[TBL] [Abstract][Full Text] [Related]
25. Harnessing gene repression to inhibit leukemia.
Harte PJ; Ernst P
Nat Med; 2015 Apr; 21(4):308-10. PubMed ID: 25849269
[No Abstract] [Full Text] [Related]
26. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
[TBL] [Abstract][Full Text] [Related]
27. The upstreams and downstreams of H3K79 methylation by DOT1L.
Vlaming H; van Leeuwen F
Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in
Campbell CT; Haladyna JN; Drubin DA; Thomson TM; Maria MJ; Yamauchi T; Waters NJ; Olhava EJ; Pollock RM; Smith JJ; Copeland RA; Blakemore SJ; Bernt KM; Daigle SR
Mol Cancer Ther; 2017 Aug; 16(8):1669-1679. PubMed ID: 28428443
[TBL] [Abstract][Full Text] [Related]
29. Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.
Dorrance AM; Liu S; Yuan W; Becknell B; Arnoczky KJ; Guimond M; Strout MP; Feng L; Nakamura T; Yu L; Rush LJ; Weinstein M; Leone G; Wu L; Ferketich A; Whitman SP; Marcucci G; Caligiuri MA
J Clin Invest; 2006 Oct; 116(10):2707-16. PubMed ID: 16981007
[TBL] [Abstract][Full Text] [Related]
30. DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation.
Song T; Zou Q; Yan Y; Lv S; Li N; Zhao X; Ma X; Liu H; Tang B; Sun L
Cell Rep; 2021 Sep; 36(12):109739. PubMed ID: 34551297
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
32. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Chang MJ; Wu H; Achille NJ; Reisenauer MR; Chou CW; Zeleznik-Le NJ; Hemenway CS; Zhang W
Cancer Res; 2010 Dec; 70(24):10234-42. PubMed ID: 21159644
[TBL] [Abstract][Full Text] [Related]
33. Drug discovery in rare indications: opportunities and challenges.
Richon VM
Hematology Am Soc Hematol Educ Program; 2013; 2013():19-23. PubMed ID: 24319157
[TBL] [Abstract][Full Text] [Related]
34. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
35. SET/MLL family proteins in hematopoiesis and leukemia.
Yang W; Ernst P
Int J Hematol; 2017 Jan; 105(1):7-16. PubMed ID: 27796741
[TBL] [Abstract][Full Text] [Related]
36. Novel therapeutic strategies for MLL-rearranged leukemias.
Wong NM; So CWE
Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
[TBL] [Abstract][Full Text] [Related]
37. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
38. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H
J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819
[TBL] [Abstract][Full Text] [Related]
39. A COMPASS in the voyage of defining the role of trithorax/MLL-containing complexes: linking leukemogensis to covalent modifications of chromatin.
Tenney K; Shilatifard A
J Cell Biochem; 2005 Jun; 95(3):429-36. PubMed ID: 15786493
[TBL] [Abstract][Full Text] [Related]
40. Expression of NG2 antigen in MLL-rearranged acute leukemias: how complex does it get?
Menendez P; Bueno C
Leuk Res; 2011 Aug; 35(8):989-90. PubMed ID: 21492935
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
